Myriad receives second insurance reimbursement decision for its BRACAnalysis in Japan

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Myriad Genetic Laboratories Inc. said the Japanese Ministry of Health, Labour, and Welfare has granted a second manufacturing and marketing approval for Myriad’s BRACAnalysis Diagnostic System as a companion diagnostic with the PARP inhibitor, Lynparza (olaparib).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login